Last reviewed · How we verify
NCT03951415: DOMEC
Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer
Phase 2 trial testing PARP inhibitor and Anti-PD-L1 in Endometrial Neoplasms in 55 participants. Status unknown.
1 August 2021
Quick facts
| Lead sponsor | Leiden University Medical Center |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 55 |
| Start date | 8 July 2019 |
| Primary completion | 1 August 2021 |
| Estimated completion | 1 August 2021 |
| Sites | 8 locations across Netherlands |
Drugs / interventions tested
- PARP inhibitor and Anti-PD-L1 — full drug profile →
Conditions studied
- Endometrial Neoplasms — all drugs for Endometrial Neoplasms →
- Uterine Neoplasms — all drugs for Uterine Neoplasms →
- Endometrium Cancer — all drugs for Endometrium Cancer →
Sponsor
Leiden University Medical Center
Who can join
18 and older, female only, with Endometrial Neoplasms or Uterine Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The DOMEC trial is designed as a Dutch Gynecological Oncology Group (DGOG), prospective, multi-center, phase II study for 55 patients with advanced (recurrent, refractory or metastatic) endometrial cancer or carcinosarcoma of the uterus to investigate the efficacy of the combination therapy of olaparib tablets and durvalumab IV.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.
Jiang M, Jia K, Wang L, Li W, et al · · 2021 · cited 236× · PMID 34729299 · DOI 10.1016/j.apsb.2021.01.003 -
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
Peyraud F, Italiano A. · · 2020 · cited 163× · PMID 32526888 · DOI 10.3390/cancers12061502 -
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy.
van den Heerik ASVM, Horeweg N, de Boer SM, Bosse T, et al · · 2021 · cited 140× · PMID 33082238 · DOI 10.1136/ijgc-2020-001822 -
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
Wang Q, Peng H, Qi X, Wu M, et al · · 2020 · cited 114× · PMID 32728057 · DOI 10.1038/s41392-020-0199-6 -
Uterine serous carcinoma.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, et al · · 2021 · cited 110× · PMID 33934848 · DOI 10.1016/j.ygyno.2021.04.029 -
Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
Wang M, Chen S, Ao D. · · 2021 · cited 84× · PMID 34977872 · DOI 10.1002/mco2.103 -
The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation.
Fan Z, Wu C, Chen M, Jiang Y, et al · · 2022 · cited 82× · PMID 35530130 · DOI 10.1016/j.apsb.2021.09.010 -
Immunotherapy in endometrial cancer: rationale, practice and perspectives.
Cao W, Ma X, Fischer JV, Sun C, et al · · 2021 · cited 79× · PMID 34134781 · DOI 10.1186/s40364-021-00301-z
Verify or expand the search:
- PubMed search for NCT03951415
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Endometrial Neoplasms
Currently open trials in the same condition.
- NCT07114653 — The Role of POLE Mutation in High Risk Endometrial Cancer. · recruiting
- NCT07040657 — Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometria · NA · recruiting
- NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting
- NCT06751329 — A Study of DM002 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
- NCT06023862 — A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurr · Phase 2 · recruiting
Other Leiden University Medical Center trials
Trials by the same sponsor.
- NCT07312565 — Occurrence of Abdominal Aortic Aneurysms in Patients With Aneurysmal Subarachnoid Hemorrhage · not yet recruiting
- NCT07090343 — Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement · Phase 3 · not yet recruiting
- NCT07498738 — Making Diabetes Care Fit for Young Adults Living With Type 1 Diabetes: Observations, Reflections and Expert Opinions · NA · not yet recruiting
- NCT06545292 — Microsampling for Therapeutic Drug Monitoring of Oral Oncolytics in Oncology Patients · NA · recruiting
- NCT07021495 — SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03951415 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Leiden University Medical Center
- Last refreshed: 1 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03951415.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing